A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia
Aref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann · 2023
Read A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia by Aref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10726920.txt.
Description
A peer-reviewed research article from Europe PMC (2023). BackgroundDespite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL.MethodsWe conducted a single‐arm multi‐center Phase II study of sapanisertib monotherapy (3 mg orally daily of the milled formulation for 21 days every 28 days) in patients with ALL through the Experimental Therapeutics Clinical Trials Network (NCI‐9775).ResultsSixteen patients, 15 of whom were previously treated (median 3 prior lines of therapy), were enrolled.
Catalog record
| CREATOR | Aref Al‐Kali, Ibrahim Aldoss, Pamela J Atherton, Carrie A Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Sarah A Buhrow, Jianping Kong, Joel M Reid, Alex A Adjei, Scott H Kaufmann |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |